行情

XENT

XENT

Intersect ENT
NASDAQ

实时行情|Nasdaq Last Sale

18.60
+0.41
+2.25%
盘后: 18.60 0 0.01% 16:37 09/20 EDT
开盘
18.13
昨收
18.19
最高
18.75
最低
17.96
成交量
29.71万
成交额
--
52周最高
35.87
52周最低
15.01
市值
5.85亿
市盈率(TTM)
-16.5201
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

XENT 新闻

  • Bragar Eagel & Squire is Investigating Certain Officers and Directors of Intersect ENT, Floor & Décor, RCI Hospitality, and EQT Corporation and Encourages Investors to Contact the Firm
  • GlobeNewswire.3天前
  • Intersect ENT Rides on Innovation Amid Pricing Concerns
  • Zacks.4天前
  • Intersect ENT (XENT) Down 18.6% Since Last Earnings Report: Can It Rebound?
  • Zacks.08/31 13:32
  • Stocks That Hit 52-Week Lows On Thursday
  • Benzinga.08/22 15:12

更多

所属板块

医疗设备、用品及经销
+0.15%
医疗设备和用品
-0.22%

热门股票

名称
价格
涨跌幅

XENT 简况

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
展开

Webull提供Intersect ENT Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。